Dr. Chovatiya discusses how topical ruxolitibnib cream has the ability to not only stop depigmentation but help induce repigmentation by stopping the inflammatory process and allowing melanocytes back into the skin.
Dr. Elbuluk discusses results of the clinical trials for ruxolitinib cream in patients with vitiligo and how this treatment is being incorporated into the dermatologist’s vitiligo toolkit.
John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He explains how this treatment has shown exceptional efficacy with limited side effects.
Seemal Desai, MD, a board-certified dermatologist in private and academic practice in Dallas, Texas, discusses the positive impact a recent topical approval has shown for the treatment of vitiligo. He mentions the current effectiveness of excimer lasers for phototherapy as well as potential new surgical procedures on the horizon in 2023.
Susan Taylor, MD, Professor of Dermatology at The University of Pennsylvania in Philadelphia, Pennsylvania, reviews the burden of vitiligo on patients of color and reviews emerging topical and oral treatments to keep on the radar.